Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jan 27;20(4):1332-1355.
doi: 10.7150/ijbs.90982. eCollection 2024.

Polyphenols Targeting NF-κB Pathway in Neurological Disorders: What We Know So Far?

Affiliations
Review

Polyphenols Targeting NF-κB Pathway in Neurological Disorders: What We Know So Far?

Abdullah Al Mamun et al. Int J Biol Sci. .

Abstract

Polyphenolic compounds have shown promising neuroprotective properties, making them a valuable resource for identifying prospective drug candidates to treat several neurological disorders (NDs). Numerous studies have reported that polyphenols can disrupt the nuclear factor kappa B(NF-κB) pathway by inhibiting the phosphorylation or ubiquitination of signaling molecules, which further prevents the degradation of IκB. Additionally, they prevent NF-κB translocation to the nucleus and pro-inflammatory cytokine production. Polyphenols such as curcumin, resveratrol, and pterostilbene had significant inhibitory effects on NF-κB, making them promising candidates for treating NDs. Recent experimental findings suggest that polyphenols possess a wide range of pharmacological properties. Notably, much attention has been directed towards their potential therapeutic effects in NDs such as Alzheimer's disease (AD), Parkinson's disease (PD), cerebral ischemia, anxiety, depression, autism, and spinal cord injury (SCI). Much preclinical data supporting the neurotherapeutic benefits of polyphenols has been developed. Nevertheless, this study has described the significance of polyphenols as potential neurotherapeutic agents, specifically emphasizing their impact on the NF-κB pathway. This article offers a comprehensive analysis of the involvement of polyphenols in NDs, including both preclinical and clinical perspectives.

Keywords: Alzheimer's disease; NF-κB pathway; Neuroinflammation; Parkinson's disease; Polyphenols; neurological disorders; spinal cord injury.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interest exists.

Figures

Figure 1
Figure 1
Illustration represents the polyphenols targeting the NF-κB pathway associated with Alzheimer's disease. Inappropriate breakdown of amyloid precursor protein by beta and gamma-secretase results in the creation of amyloid-beta plaque, which in turn leads to mitochondrial malfunction and apoptosis, which ultimately results in Alzheimer's disease. Cytokines and toxins also are responsible for activating the NF-κB pathway, which ultimately results in inflammation in the nervous system and ultimately leads to Alzheimer's disease state.
Figure 2
Figure 2
Illustration represents the polyphenols targeting the NF-κB pathway associated with Parkinson's disease. The activation of the NF-κB, MAPK, and Nrf2 pathways by amyloid-beta plaque and neurofibrillary tangles ultimately results in the leaking of the blood-brain barrier (BBB) and neuroinflammation, which ultimately leads to Parkinson's disease.
Figure 3
Figure 3
Illustration represents the polyphenols targeting the NF-κB pathway associated with SCI. SCI is characterized by primary injury followed by secondary injury. Increased intracellular calcium ion concentration, free radical production, blood-spinal cord barrier disruption, and mass ion reflux result from primary injuries, leading to the progression of secondary injuries. In addition, spinal ischemia, oxidative stress, and neuroinflammation lead to the progression of secondary SCI.
Figure 4
Figure 4
Structures of bioactive polyphenolic compounds effective in NF-κB signaling pathway-associated neurological disorders

References

    1. Mehndiratta MM, Aggarwal V. Neurological disorders in India: past, present, and next steps. Lancet Glob Heal. 2021;9:e1043–4. - PubMed
    1. Collaborators† IS-LDBIND. The burden of neurological disorders across the states of India: the Global Burden of Disease Study 1990-2019. Lancet Glob Heal. 2021;9:e1129–44. - PMC - PubMed
    1. Borsook D. Neurological diseases and pain. Brain. 2012;135:320–44. - PMC - PubMed
    1. Rahman MH, Bajgai J, Fadriquela A. et al. Redox effects of molecular hydrogen and its therapeutic efficacy in the treatment of neurodegenerative diseases. Processes. 2021;9:1–17.
    1. Salvadores N, Court FA. The necroptosis pathway and its role in age-related neurodegenerative diseases: will it open up new therapeutic avenues in the next decade? Expert Opin Ther Targets. 2020;24:679–93. - PubMed